BioPharmSignal logoBioPharmSignal

Biotech News

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation (ABSI)Absci CorporationEarnings

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of

Related news

ABSIAbsci Corporation2026-07-14 20:05 EST

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

ABSIAbsci Corporation2026-05-07 20:06 EST

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

View all latest news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

ABSIAbsci Corporation2026-08-11 20:05 EST

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

ABSIAbsci Corporation2026-07-14 20:05 EST

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

ABSIAbsci Corporation2026-06-24 10:35 EST

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

ABSIAbsci Corporation2026-06-24 10:30 EST

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

ABSIAbsci Corporation2026-05-20 12:00 EST

Absci to Participate in Upcoming Investor Conferences

Stock data

Close
9.55 USD
Market cap
990M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States